Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | fibrillin 1 | 0.0597 | 0.98 | 0.9898 |
Schistosoma mansoni | egf-like domain protein | 0.0597 | 0.98 | 0.9898 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0601 | 0.9899 | 1 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0597 | 0.98 | 0.98 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0597 | 0.98 | 1 |
Echinococcus multilocularis | laminin | 0.0597 | 0.98 | 0.9898 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.0601 | 0.9901 | 1 |
Echinococcus granulosus | laminin | 0.0597 | 0.98 | 0.9898 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0601 | 0.9899 | 0.9899 |
Loa Loa (eye worm) | hypothetical protein | 0.0601 | 0.9899 | 0.9899 |
Echinococcus multilocularis | Tolloid protein 1 | 0.0601 | 0.9901 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0597 | 0.98 | 0.98 |
Loa Loa (eye worm) | hypothetical protein | 0.0601 | 0.9901 | 0.9901 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0601 | 0.9901 | 0.9901 |
Loa Loa (eye worm) | hypothetical protein | 0.0232 | 0.0101 | 0.0101 |
Onchocerca volvulus | 0.0248 | 0.0542 | 0.0547 | |
Loa Loa (eye worm) | hypothetical protein | 0.0248 | 0.0542 | 0.0542 |
Giardia lamblia | High cysteine protein | 0.0228 | 0 | 0.5 |
Brugia malayi | Fibulin-1 precursor | 0.0597 | 0.98 | 0.99 |
Onchocerca volvulus | Arrow homolog | 0.0601 | 0.9899 | 1 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.0232 | 0.0101 | 0.0102 |
Echinococcus granulosus | Tolloid protein 1 | 0.0601 | 0.9901 | 1 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.0597 | 0.98 | 0.99 |
Loa Loa (eye worm) | hypothetical protein | 0.0597 | 0.98 | 0.98 |
Brugia malayi | Muscle positioning protein 4 | 0.0248 | 0.0542 | 0.0547 |
Onchocerca volvulus | Putative cubilin | 0.0232 | 0.0101 | 0.0102 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0597 | 0.98 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.